Pharma & Biopharma

“Sector & Segment works with a range of pharma & biopharma players, helping them improve their market positioning in relevant therapeutic areas, both through in-depth qualitative understandings of the medical landscape and quantitative analysis of their portfolio competitiveness”

We work with a variety of pharma & biopharma companies whose distinct go-to-market models each require unique insights and strategies. For example, it can be challenging for B2B pharma players, or those who have set up a network of local distribution partnerships, to influence patient journeys, communications with HCPs and patients, and ultimately product choice. We work closely with these types of players to ensure they transmit the right information to their partners and customers to drive more business.

Other challenges we tackle with our clients include:

  • Stress testing planned product launches, or sizing the potential of product / innovation pipelines
  • Expanding applications of our client’s solutions to adjacent or new therapeutic areas, whilst adapting to regulatory conditions for market access
  • Supporting the adoption of solutions that target prevention of symptoms, diseases, or disease progression, which can be harder to build evidence for compared to curative solutions

Examples of Therapeutic Areas we have worked on:

  • Autoimmune Diseases (Lupus, Primary Humoral Immunodeficiency, Rheumatoid Arthritis)
  • Cancer (Breast, Lower/Upper GI, Head & Neck, Prostate, Lung, Uterine)
  • COPD
  • Cystic Fibrosis
  • Diabetes Type 1/2
  • Infectious Respiratory Diseases
  • Inflammatory Bowel Diseases
  • Muscular Dystrophy
  • Pain Management
  • Parkinson’s Disease
  • Stroke

Sectors Insights

Navigating Early Cancer Detection: Promises and Integration Challenges in Healthcare Systems

Navigating Early Cancer Detection: Promises and Integration Challenges in Healthcare Systems

Genomic advances revolutionize early cancer detection using DNA sequencing & liquid biopsies. Explore Multi-cancer early detection (MCED) through biomaterial & next-generation sequencing to improve outcomes, treatment, and cost-effective healthcare.
Successful patient outcomes through patient-centric education: the role manufacturers should play

Successful patient outcomes through patient-centric education: the role manufacturers should play

Patient education plays a key role in patient outcomes1 however it is often overlooked due to time constraints and patient shock at diagnosis, resulting in worst-case scenarios for the patient. A good example of ...
Key Insights and Takeaways: GIANT Health Conference in London

Key Insights and Takeaways: GIANT Health Conference in London

In December 2022, our Consulting Managers Margarita Svarceva and Peter Hays attended the GIANT Health Conference in London. The two days were filled with engaging workshops, panels, and exhibitors. The conference ...
The Value of Segmentation in Healthcare

The Value of Segmentation in Healthcare

A trend towards the personalisation of medical care Over the past decades, healthcare systems have been progressively shifting towards a more integrated and patient-centric approach to care. One form of this shift ...
How COVID-19 has impacted medical devices: the case of wound care

How COVID-19 has impacted medical devices: the case of wound care

As healthcare systems across the world scrambled to contain the spread of COVID-19 in the spring of 2020, resources were shifted away from many areas of healthcare to treat patients with the virus. The stay-at-home ...